CID company foundation (spinoff of the Vascular Therapy division of Sorin Group)
First coronary CoCr BMS Bio Inducer Surface coated gets CE mark
CID embeds a full Endovascular BMS portfolio adding a new business line to its product offering
The first coronary polymer-free DES releasing Amphilimus™ formulation gets CE mark
The first peripheral polymer-free DES releasing Amphilimus™ formulation gets CE mark for below the knee use
Opened France, Singapore and Malaysia sales offices with direct sales team.
The new coronary polymer-free Amphilimus™ eluting stent with the innovative EvenART stent architecture gets CE mark
The new coronary Cre8™ EVO specifically designed for small vessels gets CE mark
Opened Thailand sales office with direct sales team.
Both Cre8™ & Cre8™ EVO get CE mark for 1month DAPT following PCI (see product IFUs for more details)
The first peripheral self-expanding DES in the world releasing Sirolimus (the active drug inside the Amphilimus™ formulation) gets CE mark for SFA/P1 use
The first coronary NC balloon allowing 6F KB technique for the full product range gets CE mark (see product IFU for more details)